-
Atossa Therapeutics Stock Runs While Trading In Bearish Pattern
Tuesday, July 13, 2021 - 4:44pm | 347Atossa Therapeutics Inc (NASDAQ: ATOS) shares are trading higher Tuesday after retail traders were able to push the stock higher. The stock was trading on above-average volume Tuesday and was trending on social media sites throughout the day such as StockTwits. Atossa Therapeutics was up 13.42...
-
ChemoCentryx Stock Is Approaching A Key Level
Tuesday, July 6, 2021 - 1:55pm | 354ChemoCentryx Inc. (NASDAQ: CCXI) shares traded higher Tuesday after the company announced it filed an amendment to its New Drug Application for avacopan for the treatment of anti-neutrophil cytoplasmic yutoantibody associated vasculitis. The U.S. Food and Drug Administration (FDA) filing was...
-
Biopharmaceutical Company Nkarta Raises $290M In IPO
Wednesday, July 15, 2020 - 5:39am | 160Nkarta Inc. (NASDAQ: NKTX) announced on Tuesday the underwriters for its initial public offering have completely exercised their overallotment option to purchase 2.1 million additional shares. This brings the biopharmaceutical company's total amount raised in the IPO to $289.8 million. It...
-
The Tech Trader's 3 Stocks On The Move
Wednesday, May 22, 2019 - 1:36pm | 341Three stocks that had been digesting recent gains now appear to be on the rise again. ArQule, Inc. (NASDAQ: ARQL) gained 42 cents to $7.17 on 2.6 million shares Tuesday. The move, on more than 1/2 times its average volume, came on no news from the biopharmaceutical company. The stock broke out of a...
-
New Gilead Sciences CEO Has 'Breadth Of Experience' From Time At Roche, Says Bullish Raymond James
Tuesday, December 11, 2018 - 3:49pm | 401Research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced Monday it has named Daniel O'Day as its chairman of the board and CEO, effective March 1. What Happened O'Day joins Gilead after more than three decades of experience at Roche Holdings AG Basel ADR (OTC...
-
Omeros Shares Fall Over 40% On Renal Disease Trial Results
Monday, October 1, 2018 - 4:37pm | 359Biopharma Omeros Corporation (NASDAQ: OMER) released additional data Monday from the company’s OMS721 clinical trial in renal disease. What Happened Omeros shares were down 42.81 percent at $13.96 at the close monday. The Phase 2 trial measured protein levels in the...
-
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial
Monday, April 9, 2018 - 10:29am | 422NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...
-
Goldman Sachs On Specialty Pharma: Buy Catalent, Sell Valeant
Wednesday, January 24, 2018 - 12:27pm | 678Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...
-
Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't Sudden
Tuesday, September 26, 2017 - 9:01am | 318Genocea Biosciences Inc (NASDAQ: GNCA) announced a 40-percent workforce reduction Monday as it officially shifts focus to immuno-oncology and neoantigen cancer vaccines and explores strategic alternatives for its former lead candidate. The Street reacted with a sharp pullback and a Tuesday ratings...
-
Barron's Picks And Pans: Regeneron, Axalta, Alleghany And More
Saturday, May 14, 2016 - 6:24pm | 609Featured stories this weekend in Barron's ponder the prospects for a leading biopharmaceutical company, a manufacturer of automotive paints and a little-known insurance holding company. This issue also offers thoughts on economic reform from an outgoing CEO of a multinational industrial products...
-
Xencor Sees Profit-Taking After Big Pre-Market Spike
Tuesday, March 8, 2016 - 1:11pm | 396Xencor Inc (NASDAQ: XNCR) is on a roll this week, having announced Q4 2015 earnings beats Monday and initiating Phase II trials for its XmAb®5871 on two patients, one with IgG4-Related Disease and another with Systemic Lupus Erythematosus. The stock saw significant movement upward in...
-
Vetr Crowd Downgrades Tetraphase
Wednesday, December 9, 2015 - 3:04pm | 334Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) have lost nearly 75 percent of value year-to-date. The Vetr crowd downgraded Tetraphase to a rating of four stars out of a possible five. Despite a downgrade, the Vetr crowd still sees upside in Tetraphase's stock as 66 percent...
-
Barclays' Biopharmaceuticals Blueprint For 2016
Tuesday, December 1, 2015 - 12:54pm | 599Geoff Meacham of Barclays initiated coverage of six names within the "newly combined" U.S. Biopharmaceuticals sector. Meacham noted he is "positive" on the fundamentals and the "pipeline-driven evolution into a more specialty therapeutic areas." However, the...
-
IPO Outlook: Inotek's Vision For The Future
Wednesday, February 4, 2015 - 3:28pm | 1080Inotek Pharmaceuticals Corp (NASDAQ: ITEK), founded in 1999, is a clinical-stage biopharmaceutical company centered on the discovery, development and commercialization of therapies to treat glaucoma. Glaucoma is condition where the eye is unable to properly drain fluid, which leads to a buildup...
-
3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology
Sunday, August 24, 2014 - 8:08pm | 764Companies producing so-called “plantibodies,” or plant-produced antibodies created by genetic engineering, have been attracting headlines recently. San Diego-based Mapp Pharmaceutical, which was acquired last year by Allergan (NYSE: AGN), has gotten global attention over the...